Gemcitabine

For research use only. Not for use in humans.

製品コードS1714 別名：LY-188011, NSC 613327

CAS No. 95058-81-4

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 23500	あり
50mg	JPY 18100	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(119)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

製品説明

体外試験

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. ^[1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. ^[2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. ^[3]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NH6xcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfrO4lSUUN3ME2wMlAxODR3ODDuUS=>	MnH2V2FPT0WU
ES4	NGHheFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;uTVE4UUN3ME2wMlAxODZ3MzDuUS=>	MoX2V2FPT0WU
ACHN	M{XWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInKXmhKSzVyPUCuNFAxQDh5IH7N	MnHhV2FPT0WU
KYSE-510	NHfPNJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMECwPVc2KG6P	M{\wXXNCVkeHUh?=
EW-7	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjibVNKSzVyPUCuNFAzPThibl2=	MUfTRW5ITVJ?
BFTC-905	M1zJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXkTWM2OD1yLkCwOVE2KG6P	M4nSVnNCVkeHUh?=
KE-37	MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P0e2lEPTB;MD6wNFU3OSCwTR?=	Mki4V2FPT0WU
SBC-5	NYnBdYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn31TWM2OD1yLkCwOVchdk1?	MWnTRW5ITVJ?
NKM-1	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXGc\|BKSzVyPUCuNFA4ODlibl2=	MnTLV2FPT0WU
RH-1	NYX1c2Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3STWM2OD1yLkCwO\|E5KG6P	MkSwV2FPT0WU
ALL-PO	NHXoNZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMEC4N{BvVQ>?	MoHNV2FPT0WU
QIMR-WIL	M{WwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTBwMEC4PVQhdk1?	NVSx[IpqW0GQR1XS
A375	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEC5PVUhdk1?	M3\oeXNCVkeHUh?=
SIG-M5	M2TIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnERWNEUUN3ME2wMlAyODRibl2=	NUTC[2p4W0GQR1XS
KGN	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\uZmlKSzVyPUCuNFExQCCwTR?=	MmKzV2FPT0WU
EW-13	NX\XXHp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHiZY5KSzVyPUCuNFEyOiCwTR?=	NFS1fJFUSU6JRWK=
NCI-SNU-1	NV3pXoxOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XMOWlEPTB;MD6wNVYhdk1?	MknHV2FPT0WU
PSN1	NGDifmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWn2OWRjUUN3ME2wMlAyPjVibl2=	MYXTRW5ITVJ?
HUTU-80	NVvxVpdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwMEG2OkBvVQ>?	NUfaSoR5W0GQR1XS
EW-16	NVHidnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrsTWM2OD1yLkCyN{BvVQ>?	NYq0NlBFW0GQR1XS
786-0	NUXV[\|lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMEKzJI5O	NUfxNYo{W0GQR1XS
ES1	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjFemZGUUN3ME2wMlAzPjhibl2=	MoDFV2FPT0WU
RKO	NUHCb2oxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjwTWM2OD1yLkCyO\|khdk1?	M3jMPXNCVkeHUh?=
ESS-1	M{T0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTBwMEK4OkBvVQ>?	NH23RZJUSU6JRWK=
SK-UT-1	NV3UPINET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnpUFZKSzVyPUCuNFI6PyCwTR?=	MlywV2FPT0WU
LB2241-RCC	NX\3UYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjUTWM2OD1yLkCzNVghdk1?	M3XSNXNCVkeHUh?=
CHL-1	NXzaXodXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEOyOEBvVQ>?	NIjpRm5USU6JRWK=
SW1783	MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHyV3RKSzVyPUCuNFM{PiCwTR?=	MXzTRW5ITVJ?
MEL-JUSO	M3LXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTibpNsUUN3ME2wMlA{QTFibl2=	M3vCc3NCVkeHUh?=
HT-29	NV3uT4VZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTTZ4M6UUN3ME2wMlA1OTNibl2=	NEDiVFlUSU6JRWK=
SNG-M	M1[1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFf1ZlVKSzVyPUCuNFQzPSCwTR?=	NVnKWo1tW0GQR1XS
TE-15	NYfkdmFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMES2OEBvVQ>?	NG[zSYtUSU6JRWK=
HOS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUf2T5VXUUN3ME2wMlA1QCCwTR?=	MmG5V2FPT0WU
BB65-RCC	MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYO2bVl2UUN3ME2wMlA2OTJibl2=	NGG3bYZUSU6JRWK=
HCE-4	M4DzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEWyPEBvVQ>?	NY[wdGRUW0GQR1XS
MHH-ES-1	Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYX2PYhuUUN3ME2wMlA2OzFibl2=	NVnmOm1WW0GQR1XS
RPMI-7951	NILEXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnMTYxKSzVyPUCuNFU1OSCwTR?=	NGCwRoRUSU6JRWK=
IST-SL2	NIDzV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrJXnFZUUN3ME2wMlA2QDRibl2=	MkH2V2FPT0WU
CMK	NUfVfm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHz0VlFKSzVyPUCuNFU5PiCwTR?=	M{i1VHNCVkeHUh?=
GR-ST	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMEW5OUBvVQ>?	NX7PPHV5W0GQR1XS
NALM-6	M133XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXYSXNpUUN3ME2wMlA3OjJibl2=	NWD3e5VoW0GQR1XS
RPMI-6666	NX3rU3BKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki0TWM2OD1yLkC2OVIhdk1?	M3S0PHNCVkeHUh?=
LC-2-ad	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwME[1N{BvVQ>?	MXvTRW5ITVJ?
ARH-77	NUXNeJV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\VZmlEPTB;MD6wO\|EyKG6P	MoHzV2FPT0WU
IST-MEL1	NHzQV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XuRWlEPTB;MD6wO\|I3KG6P	NWPadZdSW0GQR1XS
SW1710	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXMd49KSzVyPUCuNFc2OSCwTR?=	NF3WNXlUSU6JRWK=
DEL	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwMEi4O{BvVQ>?	MWnTRW5ITVJ?
AGS	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXJWVZKSzVyPUCuNFkxOiCwTR?=	NH3KZ4hUSU6JRWK=
NCI-H2122	NFLVeWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TIdGlEPTB;MD6wPVQ3KG6P	NY\Q[5E{W0GQR1XS
HSC-4	NUD5TYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTBwMUCyJI5O	NIK0e2tUSU6JRWK=
AM-38	NHjyfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3DUoFKSzVyPUCuNVIyKG6P	NEK1dXBUSU6JRWK=
769-P	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn[yTWM2OD1yLkGyN{BvVQ>?	M17kO3NCVkeHUh?=
RT-112	NVnsdI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7JdmdIUUN3ME2wMlEzPyCwTR?=	NXfSVZVmW0GQR1XS
MCF7	M3fPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDiV2p[UUN3ME2wMlE{PiCwTR?=	M4rXd3NCVkeHUh?=
IGROV-1	M13yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETHbmZKSzVyPUCuNVQ2KG6P	NHrM[4VUSU6JRWK=
OCI-AML2	NYH6c5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnCV21KSzVyPUCuNVQ4KG6P	MojEV2FPT0WU
NCI-H1299	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEW2SYRKSzVyPUCuNVU4KG6P	NIHQXIZUSU6JRWK=
A431	NVH6c2dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXSRnhKSzVyPUCuNVg{KG6P	MVXTRW5ITVJ?
SW982	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;2V2dtUUN3ME2wMlIyOyCwTR?=	NWjlbZUxW0GQR1XS
BB30-HNC	Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFK0cpRKSzVyPUCuNlMyKG6P	NXrPOWtvW0GQR1XS
ACN	NWHRVZh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DJUWlEPTB;MD6yOFQhdk1?	NXjuTI9UW0GQR1XS
647-V	M3H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;FTWM2OD1yLkK0PEBvVQ>?	NU\ySJR4W0GQR1XS
SK-PN-DW	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi2eYhKSzVyPUCuNlY3KG6P	M4nWT3NCVkeHUh?=
LCLC-97TM1	M2rCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;2c2lEPTB;MD6yOlchdk1?	M{nVZ3NCVkeHUh?=
LB1047-RCC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zyb2lEPTB;MD6yOlkhdk1?	NWrl[3FwW0GQR1XS
A2780	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjKU3RKSzVyPUCuNlchdk1?	M1z1[XNCVkeHUh?=
C-33-A	M2XpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMkezJI5O	NVjFbZhlW0GQR1XS
NCI-H2228	NFLrWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1O3OGlEPTB;MD6zNVQhdk1?	NXi1OZk4W0GQR1XS
TE-5	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjEXmF7UUN3ME2wMlMyPiCwTR?=	MX\TRW5ITVJ?
HC-1	M1\VZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnETWM2OD1yLkOyO{BvVQ>?	M2LiXHNCVkeHUh?=
SK-MES-1	NIXJVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PLd2lEPTB;MD6zNlghdk1?	NF3QRYNUSU6JRWK=
NCI-H1355	NITZfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwM{ixJI5O	MXPTRW5ITVJ?
YKG-1	NFPwSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrXTWM2OD1yLkSxPUBvVQ>?	NGfwflRUSU6JRWK=
RS4-11	NWrlVFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrpO\|lpUUN3ME2wMlQ{OyCwTR?=	NVuwPVJNW0GQR1XS
Daoy	NYfPcmFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzXPWlLUUN3ME2wMlQ2PiCwTR?=	NUfneXRsW0GQR1XS
A3-KAW	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLGflJyUUN3ME2wMlU2OSCwTR?=	MX3TRW5ITVJ?
SK-MEL-30	NFTWOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrkfVBKSzVyPUCuOVU1KG6P	NXHjSoFbW0GQR1XS
U031	NWXGfIxVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEf6OFZKSzVyPUCuOVY2KG6P	M{WzTHNCVkeHUh?=
SK-LMS-1	NYDRSoZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnMT5BKSzVyPUCuOVc5KG6P	MoHhV2FPT0WU
ES6	NFPDSIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXEblJIUUN3ME2wMlU5PiCwTR?=	NFm4UWpUSU6JRWK=
EoL-1-cell	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPGbIpKSzVyPUCuOlE3KG6P	NH7xXoFUSU6JRWK=
NCI-H2009	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwNkG5JI5O	M3vaTXNCVkeHUh?=
A4-Fuk	NWHUN4p[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm4TWM2OD1yLk[yOkBvVQ>?	MXjTRW5ITVJ?
KYSE-270	NUP0cWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrET5AzUUN3ME2wMlY{PCCwTR?=	M13QUXNCVkeHUh?=
SK-LU-1	MmTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4e2dmlEPTB;MD62OVUhdk1?	MlnOV2FPT0WU
SW872	NVXTRllwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTBwN{[1JI5O	Mn\yV2FPT0WU
ES8	Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq3VJNGUUN3ME2wMlc5KG6P	NH70elBUSU6JRWK=
G-402	M1nJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHs[nRXUUN3ME2wMlc5PCCwTR?=	M1ThPHNCVkeHUh?=
ATN-1	NGnQbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwOEC3JI5O	NHHycG9USU6JRWK=
DoTc2-4510	NV3BOJpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Tab2lEPTB;MD65NFEhdk1?	MX;TRW5ITVJ?
MES-SA	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPzbZRKSzVyPUCuPVA2KG6P	M3;CbHNCVkeHUh?=
SF268	NHW2VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33vTmlEPTB;MD65Nlchdk1?	M{H2e3NCVkeHUh?=
SF539	NV2yNHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk[0TWM2OD1zLkCyJI5O	M3\UbnNCVkeHUh?=
NB69	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2P5R2lEPTB;MT6wOUBvVQ>?	MVPTRW5ITVJ?
8505C	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPo[pZMUUN3ME2xMlA3KG6P	NF[z[FdUSU6JRWK=
CAL-12T	NHq3PJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D3Z2lEPTB;MT6wPEBvVQ>?	NHnFc\|VUSU6JRWK=
BHY	NIPoPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTQTWM2OD1zLkG0JI5O	MV3TRW5ITVJ?
LB647-SCLC	NGfJVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M162dGlEPTB;MT6xPEBvVQ>?	MYHTRW5ITVJ?
CAL-62	NELTTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;pb491UUN3ME2xMlIzKG6P	NVn5e5NbW0GQR1XS
MEG-01	NVHifJB{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwMkegcm0>	NGL5RYhUSU6JRWK=
MG-63	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLQOJF3UUN3ME2xMlM{KG6P	M1PxRnNCVkeHUh?=
SW620	NYrEeoJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPOTWM2OD1zLkO1JI5O	NInK[2JUSU6JRWK=
A388	MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrXfHJKSzVyPUGuN\|Yhdk1?	M{TCbnNCVkeHUh?=
BCPAP	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTFwNEWgcm0>	MWXTRW5ITVJ?
P30-OHK	NWXHOJV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwNE[gcm0>	NIrtcHFUSU6JRWK=
Ca9-22	MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3joemlEPTB;MT61OEBvVQ>?	NVy2OWlJW0GQR1XS
VMRC-RCZ	MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTFwNUSgcm0>	MofEV2FPT0WU
LOXIMVI	NHPTOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XUfmlEPTB;MT62JI5O	NIrDW3NUSU6JRWK=
L-540	NWPyWFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LlW2lEPTB;MT62JI5O	NEfoTWRUSU6JRWK=
NTERA-S-cl-D1	NIXFXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTFwNkSgcm0>	MXLTRW5ITVJ?
MFH-ino	M3n0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFwNk[gcm0>	M{fuVXNCVkeHUh?=
Calu-6	M1LuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTFwN{Ogcm0>	MlT3V2FPT0WU
HEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTFwN{mgcm0>	MXrTRW5ITVJ?
CAL-33	NEnzOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTFwOEmgcm0>	NX\qTmo5W0GQR1XS
HSC-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFwOUGgcm0>	NXrSOXlJW0GQR1XS
KU812	M3HuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTFwOUGgcm0>	MVHTRW5ITVJ?
EB2	NGHqU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fEWWlEPTB;Mj6wNUBvVQ>?	MXHTRW5ITVJ?
SR	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXCTWM2OD1{LkGyJI5O	NHWye45USU6JRWK=
NCI-H2087	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDvb5JHUUN3ME2yMlE1KG6P	M2npUnNCVkeHUh?=
H4	NVqzXm16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJwMUigcm0>	Mn;UV2FPT0WU
EW-1	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLBOJQ{UUN3ME2yMlIzKG6P	MVjTRW5ITVJ?
MC-IXC	NXfNWog{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPSZVhWUUN3ME2yMlI3KG6P	NHLrPWtUSU6JRWK=
NCI-H727	M2nDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nuNGlEPTB;Mj61NUBvVQ>?	NXzKfJVJW0GQR1XS
MRK-nu-1	M1rvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDCfGNKSzVyPUKuOVchdk1?	MkDiV2FPT0WU
COLO-668	NF7xT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHWwUllKSzVyPUKuOlYhdk1?	M3zRUHNCVkeHUh?=
CGTH-W-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXWVoxMUUN3ME2yMlczKG6P	NEnLTZVUSU6JRWK=
CHP-212	NGHkd\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfITWM2OD1{Lke1JI5O	MV\TRW5ITVJ?
GI-1	M{T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJwN{[gcm0>	NGC5eI1USU6JRWK=
HCC1806	NWSwNJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jt[mlEPTB;Mj65NUBvVQ>?	NGfXcWxUSU6JRWK=
HLE	M2fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHrS4JKSzVyPUOgcm0>	M1H1TXNCVkeHUh?=
HSC-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLtTWM2OD1\|LkCzJI5O	Mkn5V2FPT0WU
DMS-273	NHu4[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPwTWM2OD1\|LkC3JI5O	NFK3c4dUSU6JRWK=
DU-4475	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjXZnRKSzVyPUOuNVQhdk1?	NFPybpFUSU6JRWK=
LXF-289	NILBb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPtZ295UUN3ME2zMlMyKG6P	MYPTRW5ITVJ?
PANC-03-27	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfsbFRKSzVyPUOuOVEhdk1?	M1zpNXNCVkeHUh?=
GAMG	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHaeHg1UUN3ME2zMlc1KG6P	Mof1V2FPT0WU
NCI-H522	NWfZUpRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moi0TWM2OD12LkO0JI5O	Mk\iV2FPT0WU
SW626	M3vyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\5TWM2OD12LkS2JI5O	NWXEZ2U1W0GQR1XS
HT-144	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK0VXZmUUN3ME20MlkzKG6P	MXTTRW5ITVJ?
MEL-HO	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\HcWlEPTB;NT6xOkBvVQ>?	MUfTRW5ITVJ?
BE-13	M4Pt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHCTWM2OD13LkKxJI5O	NX2yOYh6W0GQR1XS
VA-ES-BJ	M4TPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTVwMk[gcm0>	MmPNV2FPT0WU
NCI-H441	NFjpNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfBXVhKSzVyPUWuOkBvVQ>?	NI\zToJUSU6JRWK=
KP-4	NEizblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHWy[Y5KSzVyPUWuOlEhdk1?	MUfTRW5ITVJ?
LoVo	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET5eVNKSzVyPUWuO\|Ehdk1?	MkO0V2FPT0WU
HT-1080	MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq0VGdKSzVyPUWuPFMhdk1?	MlfCV2FPT0WU
GB-1	NWnae2FNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPwTWM2OD13Lki0JI5O	M4LQdXNCVkeHUh?=
IA-LM	M374Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\XRZhtUUN3ME21MlkyKG6P	M1P1dnNCVkeHUh?=
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS0SYZ[UUN3ME21Mlk{KG6P	MlzHV2FPT0WU
SK-HEP-1	NWLHW2ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfuTWM2OD14LkG0JI5O	NG[yU4tUSU6JRWK=
697	NVXLS4d2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorCTWM2OD14LkK1JI5O	M{j2OXNCVkeHUh?=
KYSE-450	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fUbmlEPTB;Nj6zNkBvVQ>?	MmLPV2FPT0WU
HCC2998	M4HzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn:zTWM2OD14LkO0JI5O	MX;TRW5ITVJ?
HD-MY-Z	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHKbmM4UUN3ME22MlY5KG6P	MnLGV2FPT0WU
OS-RC-2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH71b2ZKSzVyPU[uOlghdk1?	M3H6[HNCVkeHUh?=
SF126	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTdwMEWgcm0>	NFu5NVVUSU6JRWK=
Ca-Ski	MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTdwMEmgcm0>	MUTTRW5ITVJ?
NCI-H358	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXBRZBKSzVyPUeuNVYhdk1?	MoLTV2FPT0WU
J82	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHq2UGxKSzVyPUeuOFEhdk1?	MXzTRW5ITVJ?
NCI-H2342	NGnlelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\UemxnUUN3ME23MlY{KG6P	NGrxfHdUSU6JRWK=
OVCAR-8	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHOS5FKSzVyPUeuPUBvVQ>?	Mn\0V2FPT0WU
TE-8	NXTwe4kyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fYSWlEPTB;ODDuUS=>	MYjTRW5ITVJ?
ETK-1	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnFcINkUUN3ME24MlA5KG6P	M4W2WnNCVkeHUh?=
HAL-01	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\remlEPTB;OD6yJI5O	Moj6V2FPT0WU
KYSE-150	NG\mbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W4[mlEPTB;OD60O{BvVQ>?	NH76VpVUSU6JRWK=
NCI-H810	M4nNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHBUodSUUN3ME24MlU3KG6P	M1TjVHNCVkeHUh?=
ONS-76	NXeyTnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjlWmpKSzVyPUiuOlghdk1?	MnzJV2FPT0WU
NMC-G1	NHnhVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Lw[GlEPTB;OD63OkBvVQ>?	NWPhVJdEW0GQR1XS
C3A	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzXd2NKSzVyPUiuPFQhdk1?	MnHaV2FPT0WU
PA-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDXVm5KSzVyPUiuPVkhdk1?	M1;qXnNCVkeHUh?=
SH-4	NVfqOZhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTlwMEKgcm0>	NYDsN4NDW0GQR1XS
EFO-27	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTlwMEWgcm0>	MVjTRW5ITVJ?
CAPAN-1	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTlwMkOgcm0>	M4LtbnNCVkeHUh?=
DU-145	NFH2cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnISmxNUUN3ME25MlI6KG6P	MVXTRW5ITVJ?
A101D	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7kTWM2OD17LkO3JI5O	NVu0SGNiW0GQR1XS
ST486	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTlwNEGgcm0>	MUjTRW5ITVJ?
NCI-H1437	NEX2fIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX6TWM2OD17LkSyJI5O	NF:zcIxUSU6JRWK=
HGC-27	M4TDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTlwNjDuUS=>	MWPTRW5ITVJ?
8305C	NYrES\|I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHQToxKSzVyPUmuOlQhdk1?	MX7TRW5ITVJ?
OCUB-M	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkn3TWM2OD1zMD6wN{BvVQ>?	NVnscpFPW0GQR1XS
COLO-679	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTFyLkC3JI5O	MWLTRW5ITVJ?
Detroit562	M3rLVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELuOJpKSzVyPUGwMlQzKG6P	NYjt[Xd4W0GQR1XS
A204	MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTFzLkG2JI5O	MU\TRW5ITVJ?
NCI-H1734	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjL[WVKSzVyPUGxMlI6KG6P	M2XtZ3NCVkeHUh?=
MC-CAR	NFLld2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFzLkW4JI5O	MoXhV2FPT0WU
NCI-H2170	NIPINlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDGcodvUUN3ME2xNU46PyCwTR?=	NEH6[2FUSU6JRWK=
NCI-SNU-5	NWrZ[3pbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXURmVDUUN3ME2xNk4yOyCwTR?=	M4\WZ3NCVkeHUh?=
HCE-T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvjTWM2OD1zMj60NkBvVQ>?	NEPzSnhUSU6JRWK=
KYSE-180	NHPSRXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTF{LkixJI5O	MXXTRW5ITVJ?
C8166	NVLzSnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF\|LkC4JI5O	MlfNV2FPT0WU
NCI-H460	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGT0ZoZKSzVyPUGzMlU1KG6P	NXXLe2hkW0GQR1XS
SNU-449	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L3bWlEPTB;MUOuO\|chdk1?	NEnMN\|FUSU6JRWK=
MDA-MB-468	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPsN5BKSzVyPUG0MlEzKG6P	NH;QOJFUSU6JRWK=
COR-L23	NHLNOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTF2LkGzJI5O	Ml3zV2FPT0WU
CTV-1	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTxTWM2OD1zND6xOEBvVQ>?	Mn;uV2FPT0WU
BL-41	NGXOcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLYTWM2OD1zND6zO{BvVQ>?	MVjTRW5ITVJ?
IGR-1	NH2yelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTF2LkSyJI5O	M2W4WXNCVkeHUh?=
TK10	MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfETWM2OD1zND60PUBvVQ>?	Ml32V2FPT0WU
REH	M1y3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFq5UoRKSzVyPUG0MlUyKG6P	NUn3PFcxW0GQR1XS
LU-139	NHT2WYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\rPIZKSzVyPUG0MlU6KG6P	M3\2SnNCVkeHUh?=
KP-N-YS	MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfZNJREUUN3ME2xOE46PyCwTR?=	MWnTRW5ITVJ?
PANC-10-05	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\2WJEzUUN3ME2xOU4{QCCwTR?=	M{PTb3NCVkeHUh?=
HL-60	NHqzSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHifWVKSzVyPUG1MlY6KG6P	M{nZS3NCVkeHUh?=
T84	NHvKUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rQOWlEPTB;MUWuPVYhdk1?	NGGyeHFUSU6JRWK=
RPMI-8226	M3fHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTF4LkCyJI5O	MYHTRW5ITVJ?
UM-UC-3	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvSTWM2OD1zNj6xOkBvVQ>?	MWjTRW5ITVJ?
TE-10	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjjcW1KSzVyPUG2MlIyKG6P	MXPTRW5ITVJ?
CAL-148	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TWNWlEPTB;MUeuNlMhdk1?	NETtNWFUSU6JRWK=
BV-173	NFvHXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXWTWM2OD1zNz6yO{BvVQ>?	Moq2V2FPT0WU
Calu-3	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTIS4FKSzVyPUG3MlI6KG6P	NV\LXWtCW0GQR1XS
RPMI-2650	NFjGfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3GfFFrUUN3ME2xO{42QSCwTR?=	NYfSW\|l5W0GQR1XS
MKN45	NXP2e4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmW2TWM2OD1zNz63N{BvVQ>?	NX\pdW1LW0GQR1XS
NUGC-3	M4LQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHZblNsUUN3ME2xPE4{PCCwTR?=	NGfxO2FUSU6JRWK=
NCI-H520	MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTF6Lke3JI5O	NFjCNnlUSU6JRWK=
CCRF-CEM	NYW3U2ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXRTWM2OD1zOD64OUBvVQ>?	MlnCV2FPT0WU
NCI-H2405	M2KzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z6e2lEPTB;MUmuNUBvVQ>?	MUPTRW5ITVJ?
ES7	NIrUNphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjpeJJKSzVyPUG5Mlc3KG6P	NVfvc2M{W0GQR1XS
BPH-1	NHzwOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJyLkK4JI5O	M{LxNnNCVkeHUh?=
SAS	NFPEW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJyLkWgcm0>	M2jDeXNCVkeHUh?=
HuCCT1	NFfJS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzkSWlpUUN3ME2yNE42QCCwTR?=	NGT2[XpUSU6JRWK=
LOUCY	NX72SGkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTJyLk[2JI5O	MlHLV2FPT0WU
NCI-H292	NWDsNJJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTJyLke5JI5O	MkXuV2FPT0WU
G-361	NIWwbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlq0TWM2OD1{MT6wO{BvVQ>?	MVrTRW5ITVJ?
M059J	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPXXXlKSzVyPUKxMlA5KG6P	MVrTRW5ITVJ?
NCI-H1651	NXK2Z3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TxRWlEPTB;MkGuNVEhdk1?	MYfTRW5ITVJ?
KALS-1	NX3HRosxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvCTWM2OD1{MT6zPUBvVQ>?	NHvuRmNUSU6JRWK=
DJM-1	NGXYNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3zVppKSzVyPUKxMlU6KG6P	M2mwNnNCVkeHUh?=
AU565	M3XGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJzLkizJI5O	MmHmV2FPT0WU
HCC38	M2LYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fveWlEPTB;MkGuPVUhdk1?	MnL2V2FPT0WU
U251	NWDS[oEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1myR2lEPTB;MkKuNlchdk1?	MVzTRW5ITVJ?
ABC-1	NFLOdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTJ{Lk[1JI5O	M1TpUHNCVkeHUh?=
SK-NEP-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTJ{LkmzJI5O	NGH2dVhUSU6JRWK=
CESS	NVvWc2JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTKVGllUUN3ME2yN{4yQSCwTR?=	Mli0V2FPT0WU
MIA-PaCa-2	NVvBXIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ\|LkO2JI5O	MnO1V2FPT0WU
SUP-T1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPN[\|VKSzVyPUKzMlQ4KG6P	MoTGV2FPT0WU
L-428	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfB[YxKSzVyPUKzMlYzKG6P	MknEV2FPT0WU
SW954	MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jQdWlEPTB;MkOuOlghdk1?	NXe3PWZ{W0GQR1XS
HO-1-N-1	MmPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTJ\|Lke3JI5O	MX7TRW5ITVJ?
CHP-126	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moi3TWM2OD1{ND6xOEBvVQ>?	Mn25V2FPT0WU
HMV-II	NIrre4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XlV2lEPTB;MkSuN\|Qhdk1?	NWnuOoZRW0GQR1XS
NB10	NGfSeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTJ2LkO3JI5O	MUHTRW5ITVJ?
A172	NUHoc3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPSUlVSUUN3ME2yOE44OSCwTR?=	NV\uWVljW0GQR1XS
MONO-MAC-6	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3xdpBKSzVyPUK0Mlg1KG6P	MYXTRW5ITVJ?
NCI-H1650	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJ3LkSgcm0>	NUjhXJBSW0GQR1XS
NH-12	M3O1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\le41KSzVyPUK1MlUhdk1?	M1j6fHNCVkeHUh?=
ML-2	NGDvb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PpeWlEPTB;MkWuO\|Qhdk1?	NF2xPWtUSU6JRWK=
MZ2-MEL	NGi3[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHr4N4RKSzVyPUK2MlIzKG6P	Mn\6V2FPT0WU
COLO-684	NWLzS4RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIC1VpNKSzVyPUK2MlQyKG6P	MWjTRW5ITVJ?
HuP-T4	NFrqVYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnK4TWM2OD1{Nz6zJI5O	M4L1TnNCVkeHUh?=
SW837	M4jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkmyTWM2OD1{Nz62NkBvVQ>?	MmDZV2FPT0WU
MDA-MB-231	NULKWXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mni5TWM2OD1{Nz63PEBvVQ>?	MYPTRW5ITVJ?
KYSE-140	NGW5dm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXOTWM2OD1{Nz65NUBvVQ>?	M1jLd3NCVkeHUh?=
NOMO-1	NUT0elJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHnvb4NKSzVyPUK4MlY5KG6P	NIPySIZUSU6JRWK=
GP5d	NVezOnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XHNGlEPTB;MkiuO\|Ihdk1?	NHyxN5FUSU6JRWK=
COR-L105	M{T2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvzV3BKSzVyPUK5MlQzKG6P	NWTCZ3hNW0GQR1XS
LS-411N	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTJ7Lki4JI5O	NFnuV3BUSU6JRWK=
NY	NWHLelBCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrvZoFKSzVyPUOwMlE5KG6P	MlrPV2FPT0WU
NCI-H2030	M1njXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlO4TWM2OD1\|MD60OUBvVQ>?	MojkV2FPT0WU
CCF-STTG1	NV\nZVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTNzLkSyJI5O	NHjrOINUSU6JRWK=
NCI-H1703	NV:1d5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDXOXV{UUN3ME2zNU44QCCwTR?=	NYf1N5o6W0GQR1XS
TUR	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17r[2lEPTB;M{KuNFMhdk1?	NYDr[nl5W0GQR1XS
NOS-1	NFO4WXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jnTGlEPTB;M{KuOFQhdk1?	NYL5XYgyW0GQR1XS
A2058	NHi4T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTN{LkizJI5O	MWfTRW5ITVJ?
LCLC-103H	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDER\|VKSzVyPUOzMlI2KG6P	M33iXnNCVkeHUh?=
NCI-H510A	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvUfW1KSzVyPUOzMlI4KG6P	NXrNSFg{W0GQR1XS
BC-1	NX\uVmt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH63Nm1KSzVyPUOzMlc4KG6P	NWTnR5RZW0GQR1XS
SK-CO-1	M4nydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vzfGlEPTB;M{SuNFEhdk1?	NWfnU\|hRW0GQR1XS
A673	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG3TWM2OD1\|ND6xO{BvVQ>?	M13tS3NCVkeHUh?=
VM-CUB-1	M4P4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPqTo06UUN3ME2zOE43QSCwTR?=	NVvjWJV4W0GQR1XS
HH	M4DZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTN3LkC2JI5O	NFPpdYlUSU6JRWK=
CAL-27	NIm5OXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LnSWlEPTB;M{WuNVYhdk1?	NXnKXmlYW0GQR1XS
NEC8	M4fac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPpdYJKSzVyPUO1MlM4KG6P	NUHoNYdWW0GQR1XS
BxPC-3	NHvlXXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTN4LkmxJI5O	MonwV2FPT0WU
SNB75	NFL3W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO0dmdKSzVyPUO3MlI1KG6P	NH;TbZhUSU6JRWK=
NB13	NEi5VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXjTWM2OD1\|OD6yN{BvVQ>?	NYDWXGV{W0GQR1XS
SK-OV-3	NITVN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofTTWM2OD1\|OD63OEBvVQ>?	MUDTRW5ITVJ?
ME-180	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTN6Lkigcm0>	M17YOHNCVkeHUh?=
JiyoyeP-2003	Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDVOIVKSzVyPUO5MlM5KG6P	NYPRNG5[W0GQR1XS
LU-134-A	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXoVY5KSzVyPUSwMlAzKG6P	NXzLWJBOW0GQR1XS
LS-123	NH7QUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\TSZpUUUN3ME20NE4zQCCwTR?=	MWDTRW5ITVJ?
COLO-800	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTRyLkW2JI5O	NFziW3RUSU6JRWK=
LB831-BLC	M{HQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTRzLki1JI5O	NUTGUVVoW0GQR1XS
NCI-H747	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPWSJFKSzVyPUSyMlI5KG6P	NYrybo9rW0GQR1XS
MZ7-mel	NV;HUJBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTR{Lk[2JI5O	NH3Qc3pUSU6JRWK=
GT3TKB	NVLG[mhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjre4hKSzVyPUSyMlczKG6P	MVzTRW5ITVJ?
MOLT-16	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH70TZRKSzVyPUSzMlA2KG6P	MmnJV2FPT0WU
23132-87	NHHFcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTuV45KSzVyPUSzMlA2KG6P	NYLlTm4{W0GQR1XS
PF-382	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nsTGlEPTB;NESuNlIhdk1?	NXnyW\|lrW0GQR1XS
ES3	MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHj2PWdKSzVyPUS0MlYhdk1?	MlTjV2FPT0WU
SW756	NFrjO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTR3LkG0JI5O	MoXYV2FPT0WU

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p70S6K1 / p-S6 / HIF-1α ; PubMed: 27765914 Oncotarget Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control. PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; PubMed: 24409315 PLoS One AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting.	27765914 24409315
Immunofluorescence	Bim1; PubMed: 27177084 Oncotarget Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.	27177084
Growth inhibition assay	Cell viability; PubMed: 27765914 Oncotarget A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment.	27765914

体内試験

Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm³. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. ^[2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. ^[4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. ^[5]

お薦めの試験操作（参考用のみ）

参考

- 合併

溶解度 (25°C)

体外	DMSO	52 mg/mL (197.56 mM)
	Water	52 mg/mL warmed (197.56 mM)
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): water (warmed) 混合させたのち直ちに使用することを推奨します。	52mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Gemcitabine SDFをダウンロードする

分子量	263.2
化学式	C₉H₁₁F₂N₃O₄
CAS No.	95058-81-4
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	LY-188011, NSC 613327
Smiles	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04383119	Not yet recruiting	Drug: Trabectedin\|Drug: Gemcitabine	Leiomyosarcoma of Ovary\|Soft Tissue Sarcoma	Italian Sarcoma Group\|PharmaMar	September 1 2020	Phase 2
NCT04521686	Recruiting	Drug: LY3410738	Cholangiocarcinoma\|Chondrosarcoma\|Glioma\|Any Solid Tumor	Loxo Oncology Inc.\|Eli Lilly and Company	August 2020	Phase 1
NCT04338763	Not yet recruiting	Drug: RP72\|Drug: Gemcitabine	Pancreatic Cancer\|Pancreatic Cancer Non-resectable\|Pancreatic Cancer Metastatic	Rise Biopharmaceuticals Inc.\|Amarex Clinical Research	April 30 2020	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?
回答：
Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品

SCR7

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).
Blasticidin S HCl

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin

Cisplatin (cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine HCl

Gemcitabine HCl (LY188011) is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Oxaliplatin

Oxaliplatin (L-OHP) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.
Bleomycin Sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

研究分野別

製品類型

Gemcitabine

文献中Selleckの製品使用例(119)

製品安全説明書

DNA/RNA Synthesis阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Gemcitabine SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-09-01)

技術サポート

よくある質問（FAQ）

DNA/RNA Synthesisシグナル伝達経路

相関DNA/RNA Synthesis製品